357 related articles for article (PubMed ID: 19864144)
1. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown.
Houslay MD
Trends Biochem Sci; 2010 Feb; 35(2):91-100. PubMed ID: 19864144
[TBL] [Abstract][Full Text] [Related]
2. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA).
Collins DM; Murdoch H; Dunlop AJ; Charych E; Baillie GS; Wang Q; Herberg FW; Brandon N; Prinz A; Houslay MD
Cell Signal; 2008 Dec; 20(12):2356-69. PubMed ID: 18845247
[TBL] [Abstract][Full Text] [Related]
3. Numerous distinct PKA-, or EPAC-based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4 coordination of cell adhesion.
Raymond DR; Wilson LS; Carter RL; Maurice DH
Cell Signal; 2007 Dec; 19(12):2507-18. PubMed ID: 17884339
[TBL] [Abstract][Full Text] [Related]
4. Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases.
Baillie GS
FEBS J; 2009 Apr; 276(7):1790-9. PubMed ID: 19243430
[TBL] [Abstract][Full Text] [Related]
5. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
Houslay MD; Adams DR
Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918
[TBL] [Abstract][Full Text] [Related]
6. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK.
Li X; Vadrevu S; Dunlop A; Day J; Advant N; Troeger J; Klussmann E; Jaffrey E; Hay RT; Adams DR; Houslay MD; Baillie GS
Biochem J; 2010 Apr; 428(1):55-65. PubMed ID: 20196770
[TBL] [Abstract][Full Text] [Related]
7. AKAP signaling complexes: getting to the heart of the matter.
McConnachie G; Langeberg LK; Scott JD
Trends Mol Med; 2006 Jul; 12(7):317-23. PubMed ID: 16809066
[TBL] [Abstract][Full Text] [Related]
8. Type 4 phosphodiesterase-dependent pathways: role in inflammatory processes.
Jacob C; Martin-Chouly C; Lagente V
Therapie; 2002; 57(2):163-8. PubMed ID: 12185965
[TBL] [Abstract][Full Text] [Related]
9. In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10).
McCahill A; Campbell L; McSorley T; Sood A; Lynch MJ; Li X; Yan C; Baillie GS; Houslay MD
Cell Signal; 2008 Nov; 20(11):2071-83. PubMed ID: 18721873
[TBL] [Abstract][Full Text] [Related]
10. The molecular machinery for cAMP-dependent immunomodulation in T-cells.
Taskén K; Stokka AJ
Biochem Soc Trans; 2006 Aug; 34(Pt 4):476-9. PubMed ID: 16856837
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
12. Real-time monitoring of phosphodiesterase inhibition in intact cells.
Herget S; Lohse MJ; Nikolaev VO
Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
14. Spatiotemporal control of cAMP signalling processes by anchored signalling complexes.
Jarnaess E; Taskén K
Biochem Soc Trans; 2007 Nov; 35(Pt 5):931-7. PubMed ID: 17956249
[TBL] [Abstract][Full Text] [Related]
15. Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes.
Baillie GS; Houslay MD
Curr Opin Cell Biol; 2005 Apr; 17(2):129-34. PubMed ID: 15780588
[TBL] [Abstract][Full Text] [Related]
16. Resolution of cAMP signals in three-dimensional microdomains using novel, real-time sensors.
Karpen JW; Rich TC
Proc West Pharmacol Soc; 2004; 47():1-5. PubMed ID: 15633600
[TBL] [Abstract][Full Text] [Related]
17. PDE4 control on cAMP/PKA compartmentation revealed by biosensor imaging in neurons.
Vincent P; Castro LR; Gervasi N; Guiot E; Brito M; Paupardin-Tritsch D
Horm Metab Res; 2012 Sep; 44(10):786-9. PubMed ID: 22581649
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar SG; Rajagopal D; Ray A
Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
[TBL] [Abstract][Full Text] [Related]
19. Compartmentalization of PDE-4 and cAMP-dependent protein kinase in neutrophils and macrophages during phagocytosis.
Pryzwansky KB; Kidao S; Merricks EP
Cell Biochem Biophys; 1998; 28(2-3):251-75. PubMed ID: 9515168
[TBL] [Abstract][Full Text] [Related]
20. cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling.
Huston E; Houslay TM; Baillie GS; Houslay MD
Biochem Soc Trans; 2006 Aug; 34(Pt 4):504-9. PubMed ID: 16856845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
